APA (7th ed.) Citation

Raskob, G. E., Spyropoulos, A. C., Spiro, T. E., Lu, W., Yuan, Z., Levitan, B., . . . Barnathan, E. S. (2021). Benefit–Risk of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness: Pooled Analysis From MAGELLAN and MARINER. Wiley.

Chicago Style (17th ed.) Citation

Raskob, Gary E., Alex C. Spyropoulos, Theodore E. Spiro, Wentao Lu, Zhong Yuan, Bennett Levitan, Eunyoung Suh, and Elliot S. Barnathan. Benefit–Risk of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness: Pooled Analysis From MAGELLAN and MARINER. Wiley, 2021.

MLA (8th ed.) Citation

Raskob, Gary E., et al. Benefit–Risk of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness: Pooled Analysis From MAGELLAN and MARINER. Wiley, 2021.